Department of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, 215168, Jiangsu, China.
National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, 215123, Jiangsu, China.
J Transl Med. 2023 Oct 18;21(1):737. doi: 10.1186/s12967-023-04606-5.
BRAF non-V600 mutation occupies a relatively small but critical subset in colorectal cancer (CRC). However, little is known about the biological functions and impacts of BRAF class III mutation in CRC. Here, we aim to explore how D594A mutation impacts on biological behaviors and immune related signatures in murine CRC cells.
BRAF V600E (class I), G469V (class II) and D594A (class III) mutant cell lines were established based on MC38 cells. The biological behaviors of cells were evaluated in respect of cell growth, cell proliferation, cell apoptosis, cell migration and invasion by the methods of colony-forming assay, CCK-8 assay, Annexin V/PI staining and transwell assay. The concentrations of soluble cytokines were detected by ELISA. The membrane expression of immuno-modulatory molecules and the pattern of tumor infiltrating lymphocyte were evaluated by flow cytometry. The molecular mechanism was explored by RNA sequencing. Immunohistochemistry (IHC) staining was used for the detection of CD8α in tumor tissues. qRT-PCR and western blot were performed to assess the mRNA and protein expression. Anti-PD-L1 treatment and cytokines neutralization experiments were conducted in in vivo models.
D594A mutant cells displayed lower grade malignancy characteristics than V600E (class I) and G469V (class II) mutant cells. Meanwhile, D594A mutation led to evident immuno-modulatory features including upregulation of MHC Class I and PD-L1. In vivo experiments displayed that the frequency of infiltrated CD8 T cells was significantly high within D594A mutant tumors, which may provide potential response to anti-PD-L1 therapy. RNA sequencing analysis showed that D594A mutation led to enhanced expression of ATF3 and THBS1, which thus facilitated CXCL9 and CXCL10 production upon IFN-γ treatment. In addition, CXCL9 or CXCL10 neutralization reduced the infiltration of CD8 T cells into THBS1-overexpressing tumors.
D594A mutant CRC exhibited lower aggressiveness and immune-activated phenotype. ATF3-THBS1-CXCL9/CXCL10 axis mediated functional CD8 T cells infiltration into the microenvironment of D594A mutant CRC. Our present study is helpful to define this mutation in CRC and provide important insights in designing effective immunotherapeutic strategies in clinic.
BRAF 非 V600 突变在结直肠癌(CRC)中占据相对较小但至关重要的亚群。然而,对于 CRC 中 BRAF Ⅲ类突变的生物学功能和影响知之甚少。在这里,我们旨在探索 D594A 突变如何影响鼠 CRC 细胞的生物学行为和免疫相关特征。
基于 MC38 细胞建立 BRAF V600E(Ⅰ类)、G469V(Ⅱ类)和 D594A(Ⅲ类)突变细胞系。通过集落形成试验、CCK-8 试验、Annexin V/PI 染色和 Transwell 试验评估细胞生长、细胞增殖、细胞凋亡、细胞迁移和侵袭的生物学行为。通过 ELISA 检测可溶性细胞因子的浓度。通过流式细胞术评估免疫调节分子的膜表达和肿瘤浸润淋巴细胞的模式。通过 RNA 测序探索分子机制。免疫组织化学(IHC)染色用于检测肿瘤组织中的 CD8α。进行 qRT-PCR 和 Western blot 以评估 mRNA 和蛋白表达。在体内模型中进行抗 PD-L1 治疗和细胞因子中和实验。
与 V600E(Ⅰ类)和 G469V(Ⅱ类)突变细胞相比,D594A 突变细胞显示出较低的恶性程度特征。同时,D594A 突变导致明显的免疫调节特征,包括 MHC Class I 和 PD-L1 的上调。体内实验显示,D594A 突变肿瘤内浸润的 CD8 T 细胞频率明显较高,这可能为抗 PD-L1 治疗提供潜在反应。RNA 测序分析表明,D594A 突变导致 ATF3 和 THBS1 的表达增强,从而在 IFN-γ 处理时促进 CXCL9 和 CXCL10 的产生。此外,CXCL9 或 CXCL10 中和减少了 CD8 T 细胞浸润到 THBS1 过表达肿瘤中。
D594A 突变 CRC 表现出较低的侵袭性和免疫激活表型。ATF3-THBS1-CXCL9/CXCL10 轴介导功能性 CD8 T 细胞浸润到 D594A 突变 CRC 的微环境中。本研究有助于定义 CRC 中的这种突变,并为临床设计有效的免疫治疗策略提供重要见解。